Trevi Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire•09/11/2026•16:05 ET
0
Key Highlights
- ➤$299.4 million cash supports runway into 2030 and key clinical milestones
- ➤OCEAN-2 Phase 3 initiated; topline IPF-related cough results expected second half of 2027
- ➤FDA aligned on non-IPF ILD program; Phase 2 trial expected to start first quarter 2027
- ➤Net loss widened to $21.5 million from $11.8 million year over year
- ➤LAKE Phase 2b SSRE analysis now expected early first quarter of 2027
Expert Statements
Jennifer Good, President and CEO of Trevi Therapeutics
“This is an important time of clinical execution for Trevi as we actively open sites globally and enroll patients across all three active trials”
Jennifer Good, President and CEO of Trevi Therapeutics
“We also recently aligned with the FDA on our non-IPF ILD-related chronic cough program and expect to initiate a Phase 2 dose-ranging trial in the first quarter of 2027.”
Jennifer Good, President and CEO of Trevi Therapeutics
“Chronic cough remains a significant unmet need, and we believe our dual central and peripheral mechanism may be important for the treatment of these patients.”
Jennifer Good, President and CEO of Trevi Therapeutics
“The associated respiratory hospitalizations and potential higher risk of lung transplant results in higher cost for IPF and ILD patients, where no FDA-approved therapies exist.”
Initiated Phase 3 OCEAN-2 trial for patients with IPF-related chronic cough in the third quarter; both Phase 3 OCEAN trials actively recruiting
Positive meeting with the FDA on the non-IPF ILD-related chronic cough program held in October 2026; Phase 2 dose-ranging trial expected to initiate in the first quarter of 2027
Get started
Create a free account to read the full story.